{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:58:28Z","timestamp":1785513508192,"version":"3.56.0"},"reference-count":57,"publisher":"Mattioli1885","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Introduction: IL-17 and IL-23 inhibitors have transformed the management of moderate-to-severe psoriasis and other inflammatory diseases through targeted immune modulation. Although generally well tolerated, an expanding spectrum of cutaneous adverse reactions has been reported, ranging from common paradoxical eruptions to rare immune-mediated dermatoses that may mimic primary inflammatory or autoimmune conditions. Objectives: We present a narrative review of cutaneous adverse reactions associated with IL-17 and IL-23 inhibitors. This review aims to summarize reported reaction patterns, proposed mechanisms, clinical and histopathologic features, and current diagnostic and therapeutic considerations to support clinical decision-making. Methods: We performed a narrative review of English-language literature describing cutaneous adverse reactions associated with IL-17, IL-23, and IL-12\/23 inhibitors indexed in PubMed, Google Scholar, and Web of Science from database inception through August 2025. Clinical trials, observational studies, case series, case reports, and reviews were evaluated, and findings were synthesized according to reaction phenotype. Results: Psoriasiform and eczematous eruptions represent the most frequently reported cutaneous adverse reactions and may be clinically and histologically indistinguishable from idiopathic dermatoses. Less commonly reported reactions include lupus-like syndromes, bullous pemphigoid, lichenoid drug reactions, granulomatous eruptions, and vasculitic presentations, including IgA vasculitis. Proposed mechanisms involve paradoxical alterations in immune signaling following cytokine blockade rather than direct drug toxicity, although definitive pathways remain incompletely understood. Management strategies vary according to severity and phenotype, ranging from topical therapies and continued biologic use to discontinuation of the offending agent and systemic immunosuppression. Conclusions: IL-17 and IL-23 inhibitors are associated with a diverse spectrum of cutaneous adverse reactions that require recognition due to their potential overlap with primary dermatologic diseases. A structured approach to diagnosis and management may facilitate timely intervention. Further studies are needed to clarify incidence, risk factors, mechanisms, and evidence-based treatment strategies.<\/jats:p>","DOI":"10.5826\/dpc.1603a6731","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:08:10Z","timestamp":1785510490000},"page":"6731","source":"Crossref","is-referenced-by-count":0,"title":["Cutaneous Adverse Reactions to IL-17 and IL-23 Inhibitors: A Clinical Review of Reaction Patterns"],"prefix":"10.5826","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5218-9367","authenticated-orcid":false,"given":"Ingyun","family":"Park","sequence":"first","affiliation":[{"name":"David Geffen School of Medicine, University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bayrouti","sequence":"additional","affiliation":[{"name":"Cumming School of Medicine, University of Calgary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"MacIntyre","sequence":"additional","affiliation":[{"name":"University of Illinois College of Medicine Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Le","sequence":"additional","affiliation":[{"name":"University of Kansas School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khoa","family":"Nguyen","sequence":"additional","affiliation":[{"name":"University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27750","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"10.5826\/dpc.1603a6731_ref1","doi-asserted-by":"crossref","unstructured":"Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological therapies in immune-mediated inflammatory diseases: Can biosimilars reduce access inequities? Front Pharmacol. 2019;10:279. DOI:10.3389\/fphar.2019.00279","DOI":"10.3389\/fphar.2019.00279"},{"key":"10.5826\/dpc.1603a6731_ref2","doi-asserted-by":"crossref","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397:1301-1315. DOI:10.1016\/S0140-6736(20)32549-6","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"10.5826\/dpc.1603a6731_ref3","doi-asserted-by":"crossref","unstructured":"Loft ND, Vaengebjerg S, Halling AS, Skov L, Egeberg A. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol. 2020;34:1151-1160. DOI:10.1111\/jdv.16073","DOI":"10.1111\/jdv.16073"},{"key":"10.5826\/dpc.1603a6731_ref4","doi-asserted-by":"crossref","unstructured":"Shear NH, Betts KA, Soliman AM, et al. Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. J Am Acad Dermatol. 2021;85:572-581. DOI:10.1016\/j.jaad.2021.02.057","DOI":"10.1016\/j.jaad.2021.02.057"},{"key":"10.5826\/dpc.1603a6731_ref5","doi-asserted-by":"crossref","unstructured":"Wang J, Wang C, Liu L, et al. Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review. Front Immunol. 2023;14:993057. DOI:10.3389\/fimmu.2023.993057","DOI":"10.3389\/fimmu.2023.993057"},{"key":"10.5826\/dpc.1603a6731_ref6","doi-asserted-by":"crossref","unstructured":"Brazen B, Colon J, Hobbs L, Nousari C. Paradoxical eczematous reaction in a patient with IL-17 inhibitor-treated psoriasis vulgaris. Cureus. 2024;16:e60051. DOI:10.7759\/cureus.60051","DOI":"10.7759\/cureus.60051"},{"key":"10.5826\/dpc.1603a6731_ref7","doi-asserted-by":"crossref","unstructured":"Miyagawa F. Pathogenesis of paradoxical reactions associated with targeted biologic agents for inflammatory skin diseases. Biomedicines. 2022;10:1485. DOI:10.3390\/biomedicines10071485","DOI":"10.3390\/biomedicines10071485"},{"key":"10.5826\/dpc.1603a6731_ref8","doi-asserted-by":"crossref","unstructured":"Garcovich S, De Simone C, Genovese G, et al. Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol. 2019;10:282. DOI:10.3389\/fphar.2019.00282","DOI":"10.3389\/fphar.2019.00282"},{"key":"10.5826\/dpc.1603a6731_ref9","doi-asserted-by":"crossref","unstructured":"Obijiofor C, Mazori DR, Femia AN, et al. Paradoxical granulomatous reaction to ustekinumab. JEADV Clin Pract. 2024;3:1231-1235. DOI:10.1002\/jvc2.369","DOI":"10.1002\/jvc2.369"},{"key":"10.5826\/dpc.1603a6731_ref10","doi-asserted-by":"crossref","unstructured":"Menter A, Krueger GG, Paek SY, et al. Interleukin-17 and Interleukin-23: A narrative review of mechanisms of action in psoriasis and associated comorbidities. Dermatol Ther (Heidelb). 2021;11:385-400. DOI:10.1007\/s13555-021-00483-2","DOI":"10.1007\/s13555-021-00483-2"},{"key":"10.5826\/dpc.1603a6731_ref11","doi-asserted-by":"crossref","unstructured":"Liu T, Li S, Ying S, et al. The IL-23\/IL-17 pathway in inflammatory skin diseases: From bench to bedside. Front Immunol. 2020;11:594735. DOI:10.3389\/fimmu.2020.594735","DOI":"10.3389\/fimmu.2020.594735"},{"key":"10.5826\/dpc.1603a6731_ref12","doi-asserted-by":"crossref","unstructured":"Furue M, Furue K, Tsuji G, Nakahara T. Interleukin-17A and keratinocytes in psoriasis. Int J Mol Sci. 2020;21:1275. DOI:10.3390\/ijms21041275","DOI":"10.3390\/ijms21041275"},{"key":"10.5826\/dpc.1603a6731_ref13","doi-asserted-by":"crossref","unstructured":"Davidson L, van den Reek JMPA, Bruno M, et al. Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources. Lancet Reg Health Eur. 2022;13:100266. DOI:10.1016\/j.lanepe.2021.100266","DOI":"10.1016\/j.lanepe.2021.100266"},{"key":"10.5826\/dpc.1603a6731_ref14","doi-asserted-by":"crossref","unstructured":"Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis. J Am Acad Dermatol. 2022;86:1080-1091. DOI:10.1016\/j.jaad.2020.12.010","DOI":"10.1016\/j.jaad.2020.12.010"},{"key":"10.5826\/dpc.1603a6731_ref15","doi-asserted-by":"crossref","unstructured":"Megna M, Caiazzo G, Parisi M, et al. Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role? Clin Exp Dermatol. 2022;47:918-925. DOI:10.1111\/ced.15052","DOI":"10.1111\/ced.15052"},{"key":"10.5826\/dpc.1603a6731_ref16","doi-asserted-by":"crossref","unstructured":"Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment. Gut. 2014;63:567-577. DOI:10.1136\/gutjnl-2012-302853","DOI":"10.1136\/gutjnl-2012-302853"},{"key":"10.5826\/dpc.1603a6731_ref17","doi-asserted-by":"crossref","unstructured":"Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther. 2020;20:665-672. DOI:10.1080\/14712598.2020.1727439","DOI":"10.1080\/14712598.2020.1727439"},{"key":"10.5826\/dpc.1603a6731_ref18","unstructured":"Burlando M, Megna M, Caldarola G, et al. Eczematous reactions in patients with plaque psoriasis receiving biological therapy: an observational study. Eur Rev Med Pharmacol Sci. 2024;28:4298-4301. DOI:10.26355\/eurrev_202409_36787"},{"key":"10.5826\/dpc.1603a6731_ref19","doi-asserted-by":"crossref","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA. 2020;323:1945-1960. DOI:10.1001\/jama.2020.4006","DOI":"10.1001\/jama.2020.4006"},{"key":"10.5826\/dpc.1603a6731_ref20","doi-asserted-by":"crossref","unstructured":"Parisi R, Symmons DPM, Griffiths CEM, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377-385. DOI:10.1038\/jid.2012.339","DOI":"10.1038\/jid.2012.339"},{"key":"10.5826\/dpc.1603a6731_ref21","doi-asserted-by":"crossref","unstructured":"Syed ZU, Khachemoune A. Inverse psoriasis: case presentation and review. Am J Clin Dermatol. 2011;12:143-146. DOI:10.2165\/11532060-000000000-00000","DOI":"10.2165\/11532060-000000000-00000"},{"key":"10.5826\/dpc.1603a6731_ref22","doi-asserted-by":"crossref","unstructured":"Engin B, A\u015fk\u0131n \u00d6, T\u00fcz\u00fcn Y. Palmoplantar psoriasis. Clin Dermatol. 2017;35:19-27. DOI:10.1016\/j.clindermatol.2016.09.004","DOI":"10.1016\/j.clindermatol.2016.09.004"},{"key":"10.5826\/dpc.1603a6731_ref23","doi-asserted-by":"crossref","unstructured":"Yousif J, Al-Dehneem R, Kaskas N, Gottlieb AB. A case series of patients with eczematous eruptions following IL-17 inhibitor treatment for psoriasis vulgaris. J Drugs Dermatol. 2023;22:1225-1227. DOI:10.36849\/JDD.7388","DOI":"10.36849\/JDD.7388"},{"key":"10.5826\/dpc.1603a6731_ref24","doi-asserted-by":"crossref","unstructured":"Tang X, Li Q, Zhou Y, et al. Predictive factors of atopic-like dermatitis induced by IL-17A inhibitors in patients with psoriasis: A 2-year follow-up study. J Eur Acad Dermatol Venereol. 2023;37:2509-2516. DOI:10.1111\/jdv.19394","DOI":"10.1111\/jdv.19394"},{"key":"10.5826\/dpc.1603a6731_ref25","doi-asserted-by":"crossref","unstructured":"Li Q, Li X, Li W, et al. Development of IL-17A inhibitor-induced atopic dermatitis-like rash in psoriasis patients: Insights into immune shift. Exp Dermatol. 2024;33:e14958. DOI:10.1111\/exd.14958","DOI":"10.1111\/exd.14958"},{"key":"10.5826\/dpc.1603a6731_ref26","doi-asserted-by":"crossref","unstructured":"Al-Janabi A, Alabas OA, Yiu ZZN, et al. Risk of paradoxical eczema in patients receiving biologics for psoriasis. JAMA Dermatol. 2024;160:71-79. DOI:10.1001\/jamadermatol.2023.4846","DOI":"10.1001\/jamadermatol.2023.4846"},{"key":"10.5826\/dpc.1603a6731_ref27","doi-asserted-by":"crossref","unstructured":"Erazo-Mart\u00ednez V, Tob\u00f3n GJ, Ca\u00f1as CA. Circulating and skin biopsy-present cytokines related to the pathogenesis of cutaneous lupus erythematosus. Autoimmun Rev. 2023;22:103262. DOI:10.1016\/j.autrev.2022.103262","DOI":"10.1016\/j.autrev.2022.103262"},{"key":"10.5826\/dpc.1603a6731_ref28","doi-asserted-by":"crossref","unstructured":"Trovato E, Cortonesi G, Russo F, et al. Psoriasis successfully treated with guselkumab in a patient with systemic lupus erythematosus and acquired hemophilia A. Ital J Dermatol Venerol. 2022;157:286-287. DOI:10.23736\/S2784-8671.21.07054-7","DOI":"10.23736\/S2784-8671.21.07054-7"},{"key":"10.5826\/dpc.1603a6731_ref29","doi-asserted-by":"crossref","unstructured":"Conrad C, Di Domizio J, Mylonas A, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018;9:25. DOI:10.1038\/s41467-017-02466-4","DOI":"10.1038\/s41467-017-02466-4"},{"key":"10.5826\/dpc.1603a6731_ref30","doi-asserted-by":"crossref","unstructured":"Nashi RA, Shmerling RH. Antinuclear antibody testing for the diagnosis of systemic lupus erythematosus. Rheum Dis Clin North Am. 2022;48:569-578. DOI:10.1016\/j.mcna.2020.10.003","DOI":"10.1016\/j.rdc.2022.02.012"},{"key":"10.5826\/dpc.1603a6731_ref31","doi-asserted-by":"crossref","unstructured":"Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019;15:519-532. DOI:10.1038\/s41584-019-0272-0","DOI":"10.1038\/s41584-019-0272-0"},{"key":"10.5826\/dpc.1603a6731_ref32","doi-asserted-by":"crossref","unstructured":"Siegel CH, Sammaritano LR. Systemic lupus erythematosus: A review. JAMA. 2024;331:1480-1491. DOI:10.1001\/jama.2024.2315","DOI":"10.1001\/jama.2024.2315"},{"key":"10.5826\/dpc.1603a6731_ref33","doi-asserted-by":"crossref","unstructured":"Heidari N, Hosseini S, Heidari A, et al. A systematic review of the role of interleukin-17 inhibitors in bullous pemphigoid: therapeutic and paradoxical effects. Arch Dermatol Res. 2025;317:544. DOI:10.1007\/s00403-025-04052-x","DOI":"10.1007\/s00403-025-04052-x"},{"key":"10.5826\/dpc.1603a6731_ref34","doi-asserted-by":"crossref","unstructured":"Burlando M, Capurro N, Herzum A, et al. Guselkumab-associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature. Dermatol Ther. 2022;35:e15207. DOI:10.1111\/dth.15207","DOI":"10.1111\/dth.15207"},{"key":"10.5826\/dpc.1603a6731_ref35","doi-asserted-by":"crossref","unstructured":"Wang R, Wang A, Wang M. Two cases with bullous pemphigoid relapsed after using interleukin-17A inhibitors for psoriasis: A paradoxical reaction. J Dermatol. 2023;50:956-959. DOI:10.1111\/1346-8138.16765","DOI":"10.1111\/1346-8138.16765"},{"key":"10.5826\/dpc.1603a6731_ref36","doi-asserted-by":"crossref","unstructured":"Nakayama C, Fujita Y, Watanabe M, Shimizu H. Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab. J Dermatol. 2015;42:996-998. DOI: 10.1111\/1346-8138.12943","DOI":"10.1111\/1346-8138.12943"},{"key":"10.5826\/dpc.1603a6731_ref37","doi-asserted-by":"crossref","unstructured":"Le Jan S, Muller C, Plee J, et al. IL-23\/IL-17 axis activates IL-1\u03b2-associated inflammasome in macrophages and generates an auto-inflammatory response in a subgroup of patients with bullous pemphigoid. Front Immunol. 2019;10:1972. DOI:10.3389\/fimmu.2019.01972","DOI":"10.3389\/fimmu.2019.01972"},{"key":"10.5826\/dpc.1603a6731_ref38","doi-asserted-by":"crossref","unstructured":"Pl\u00e9e J, Le Jan S, Giustiniani J, et al. Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome. Sci Rep. 2015;5:18001. DOI:10.1038\/srep18001","DOI":"10.1038\/srep18001"},{"key":"10.5826\/dpc.1603a6731_ref39","doi-asserted-by":"crossref","unstructured":"Le Jan S, Pl\u00e9e J, Vallerand D, et al. Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid. J Invest Dermatol. 2014;134:2908-2917. DOI:10.1038\/jid.2014.263","DOI":"10.1038\/jid.2014.263"},{"key":"10.5826\/dpc.1603a6731_ref40","doi-asserted-by":"crossref","unstructured":"Powers CM, Thakker S, Gulati N, et al. Bullous pemphigoid: A practical approach to diagnosis and management in the modern era. J Am Acad Dermatol. 2025;92:1337-1350. DOI:10.1016\/j.jaad.2025.01.086","DOI":"10.1016\/j.jaad.2025.01.086"},{"key":"10.5826\/dpc.1603a6731_ref41","doi-asserted-by":"crossref","unstructured":"Chou P-Y, Yu C-L, Wen C-N, Tu Y-K, Chi C-C. Bullous pemphigoid severity and levels of antibodies to BP180 and BP230: A systematic review and meta-analysis. JAMA Dermatol. 2024;160:1192-1200. DOI:10.1001\/jamadermatol.2024.3425","DOI":"10.1001\/jamadermatol.2024.3425"},{"key":"10.5826\/dpc.1603a6731_ref42","doi-asserted-by":"crossref","unstructured":"Ghiam N, Ojong O, Vasile G, Romanelli P, Kerdel F. Lichenoid drug eruption after treatment with ixekizumab for plaque psoriasis. Dermatol Online J. 2020;26. PMID: 33423430","DOI":"10.5070\/D32612051366"},{"key":"10.5826\/dpc.1603a6731_ref43","doi-asserted-by":"crossref","unstructured":"Sparks J, Sheriff S, Burruss J. Risankizumab-associated lichen planus pemphigoides. JAAD Case Rep. 2023;35:63-67. DOI:10.1016\/j.jdcr.2023.02.020","DOI":"10.1016\/j.jdcr.2023.02.020"},{"key":"10.5826\/dpc.1603a6731_ref44","doi-asserted-by":"crossref","unstructured":"Toumi A, Molva M, Bergeret B, Marque M, Stoebner PE. Lichen planus in psoriatic patients treated with interleukin 17 inhibitors: two additional cases and a literature review. Eur J Dermatol. 2022;32:795-796. DOI:10.1684\/ejd.2022.4360","DOI":"10.1684\/ejd.2022.4360"},{"key":"10.5826\/dpc.1603a6731_ref45","doi-asserted-by":"crossref","unstructured":"Capusan TM, Herrero-Moyano M, Mart\u00ednez-Mera CR, Freih-Fraih AW, Dauden E. Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event? JAAD Case Rep. 2018;4:521-523. DOI: 10.1016\/j.jdcr.2018.04.015","DOI":"10.1016\/j.jdcr.2018.04.015"},{"key":"10.5826\/dpc.1603a6731_ref46","doi-asserted-by":"crossref","unstructured":"Di Cesare A, Maglie R, Pescitelli L, Rosi E, Prignano F. Comment on \u201cOral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?\u201d JAAD Case Rep. 2019;5:138-139. DOI: DOI:10.1016\/j.jdcr.2018.10.011","DOI":"10.1016\/j.jdcr.2018.10.011"},{"key":"10.5826\/dpc.1603a6731_ref47","doi-asserted-by":"crossref","unstructured":"Powell JB, Matthews P, Rattehalli R, et al. Acute systemic sarcoidosis complicating ustekinumab therapy for chronic plaque psoriasis. Br J Dermatol. 2015;172:834-836. DOI:10.1111\/bjd.13365","DOI":"10.1111\/bjd.13365"},{"key":"10.5826\/dpc.1603a6731_ref48","doi-asserted-by":"crossref","unstructured":"Gray AR, Davies OMT, White K, Ortega-Loayza AG. Granuloma annulare following initiation of interleukin-17a antagonist. Clin Exp Dermatol. 2021;46:924-926. DOI:10.1111\/ced.14579","DOI":"10.1111\/ced.14579"},{"key":"10.5826\/dpc.1603a6731_ref49","doi-asserted-by":"crossref","unstructured":"Young PA, Su MW, Inkeles MS, et al. IgA vasculitis in the setting of biologic therapy for psoriasis and recurrent cutaneous methicillin-resistant Staphylococcus aureus colonization. Cutis. 2022;110:E4-E10. DOI:10.12788\/cutis.0636","DOI":"10.12788\/cutis.0636"},{"key":"10.5826\/dpc.1603a6731_ref50","doi-asserted-by":"crossref","unstructured":"Pulla JC, Amirjanyan H, Wu Q, et al. Cerebral Vasculitis in a patient receiving Risankizumab, an Inhibitor of Interleukin-23: First Case Report (P12-3.013). Neurology. 2023;100(suppl 17):P12-3.013. DOI:10.1212\/WNL.0000000000202476","DOI":"10.1212\/WNL.0000000000202476"},{"key":"10.5826\/dpc.1603a6731_ref51","doi-asserted-by":"crossref","unstructured":"da Silva Cendon Duran C, Barreto Santiago M. Cutaneous vasculitis during secukinumab treatment. Eur J Case Rep Intern Med. 2020;7:001815. DOI:10.12890\/2020_001815","DOI":"10.12890\/2020_001815"},{"key":"10.5826\/dpc.1603a6731_ref52","doi-asserted-by":"crossref","unstructured":"Ospina Velasquez LE, Papadakis KA, Urquhart SA. Ustekinumab-induced vasculitis in a patient with Crohn\u2019s disease. ACG Case Rep J. 2025;12:e01625. DOI:10.14309\/crj.0000000000001625","DOI":"10.14309\/crj.0000000000001625"},{"key":"10.5826\/dpc.1603a6731_ref53","doi-asserted-by":"crossref","unstructured":"Costa-Moreira P, Lopes S, Santos AL, et al. Leukocytoclastic vasculitis related to ustekinumab in a Crohn\u2019s disease patient: First case report and literature review. J Crohns Colitis. 2020;14:274-276. DOI:10.1093\/ecco-jcc\/jjz128","DOI":"10.1093\/ecco-jcc\/jjz128"},{"key":"10.5826\/dpc.1603a6731_ref54","doi-asserted-by":"crossref","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-1072. DOI:10.1016\/j.jaad.2018.11.057","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"10.5826\/dpc.1603a6731_ref55","doi-asserted-by":"crossref","unstructured":"Zhang L, Chen L, Wang H, et al. Elevated cutaneous interleukin-21 links eczematous eruption to interleukin-17A inhibitor treatment in psoriasis. Allergy. 2025. DOI:10.1111\/all.70026","DOI":"10.1111\/all.70026"},{"key":"10.5826\/dpc.1603a6731_ref56","doi-asserted-by":"crossref","unstructured":"Xiao Y, Peng S, Li X, et al. Treatment of paradoxical eczematous eruption in psoriasis treated with secukinumab: A case report. Medicine (Baltimore). 2023;102:e32844. DOI:10.1097\/MD.0000000000032844","DOI":"10.1097\/MD.0000000000032844"},{"key":"10.5826\/dpc.1603a6731_ref57","doi-asserted-by":"crossref","unstructured":"Otani IM, Levin AS, Banerji A. Cutaneous manifestations of reactions to biologics. Curr Allergy Asthma Rep. 2018;18:12. DOI:10.1007\/s11882-018-0764-z","DOI":"10.1007\/s11882-018-0764-z"}],"container-title":["Dermatology Practical &amp; Conceptual"],"original-title":[],"link":[{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/6731\/3918","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/6731\/3918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:08:18Z","timestamp":1785510498000},"score":1,"resource":{"primary":{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/view\/6731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":57,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5826\/dpc.1603a6731","relation":{"has-manifestation":[{"id-type":"other","id":"1-84-6731-g3918","asserted-by":"subject"}],"is-part-of":[{"id-type":"doi","id":"10.5826\/dpc.1603a%a","asserted-by":"subject"}]},"ISSN":["2160-9381"],"issn-type":[{"value":"2160-9381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"4"}}